Molecular engineering company Scribe Therapeutics Inc announced on Tuesday a new research collaboration with French healthcare company Sanofi SA (Euronext Paris: SAN) (NASDAQ: SNY).
Under the agreement Sanofi will use Scribe's CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.
Sanofi is granted non-exclusive rights to Scribe's CasX-Editor (XE) technology for multiple oncology targets in exchange for a USD25m upfront fee with the potential for more than USD1bn in milestone payments, as well as tiered royalties on net future sales of any products that may result from this research agreement.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval